Hence, serum level of HMGB1 has been considered to be a potential biomarker for early diagnosis of NAFLD and a therapeutic target for prevention and intervention of NAFLD-associated inflammation. The gene discussed is HMGB1; the disease is metabolic dysfunction-associated steatotic liver disease.